根据协议条款,Xilio授予吉利德全球独家许可,允许其开发和商业化Xilio的肿瘤激活的 IL-12 XTX301。Xilio将获得4,350万美元的预付款,其中包括3000万美元的现金支付以及吉利德对1350万美元Xilio普通股的溢价初始股权投资。Xilio将有资格获得高达6.04亿美元的额外或有付款,包括吉利德的额外股权投资、过渡费以及特定的开发、...
The masking domain of XTX301 is designed to pharmacologically inactivate IL-12 systemically and render an active IL-12 moiety upon cleavage by proteases that are enriched in the tumor microenvironment. Methods We conducted experiments to assess the binding, bioactivity, safety, and anti-tumor ...
Relevance to Sustainability:The review article addresses the global imperative of achieving a sustainable future, making it highly relevant to current environmental concerns.Focus on Alternative Materials:The review explores the use of alternative and eco-friendly materials for energy storage and conversion...